Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Endometrial Neoplasms 2Urinary Bladder Neoplasms 1Solid Tumor 1Pathologic Complete Response 1Ovarian Neoplasms 1Hemangiosarcoma 1

Interventions

pembrolizumab 157Gemcitabine 140Capecitabine 123Paclitaxel 121Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Docetaxel 98Leucovorin 97Cisplatin 90Radiosurgery 88Irinotecan 88Carboplatin 86Cyclophosphamide 72Cetuximab 72Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × trastuzumab duocarmazine × Clear all
NCT04602117 2023-11-18

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

QuantumLeap Healthcare Collaborative

Phase 1 Withdrawn
BreastGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02277717 2023-08-14

First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients

Byondis B.V.

Phase 1 Completed
185 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡